DRUG vs. MEIP, FBRX, TXMD, LGVN, CARA, JAN, KALA, IBIO, APM, and ALTS
Should you be buying Bright Minds Biosciences stock or one of its competitors? The main competitors of Bright Minds Biosciences include MEI Pharma (MEIP), Forte Biosciences (FBRX), TherapeuticsMD (TXMD), Longeveron (LGVN), Cara Therapeutics (CARA), JanOne (JAN), KALA BIO (KALA), iBio (IBIO), Aptorum Group (APM), and Janone (ALTS). These companies are all part of the "pharmaceutical products" industry.
Bright Minds Biosciences (NASDAQ:DRUG) and MEI Pharma (NASDAQ:MEIP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, community ranking, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.
Bright Minds Biosciences has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500. Comparatively, MEI Pharma has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.
MEI Pharma's return on equity of 48.32% beat Bright Minds Biosciences' return on equity.
MEI Pharma received 385 more outperform votes than Bright Minds Biosciences when rated by MarketBeat users.
In the previous week, MEI Pharma had 11 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 12 mentions for MEI Pharma and 1 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.92 beat MEI Pharma's score of -0.15 indicating that Bright Minds Biosciences is being referred to more favorably in the media.
Bright Minds Biosciences has higher earnings, but lower revenue than MEI Pharma. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than MEI Pharma, indicating that it is currently the more affordable of the two stocks.
40.5% of Bright Minds Biosciences shares are held by institutional investors. Comparatively, 52.4% of MEI Pharma shares are held by institutional investors. 42.7% of Bright Minds Biosciences shares are held by company insiders. Comparatively, 3.9% of MEI Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
MEI Pharma has a consensus target price of $7.00, suggesting a potential upside of 104.68%. Given MEI Pharma's higher probable upside, analysts plainly believe MEI Pharma is more favorable than Bright Minds Biosciences.
Summary
MEI Pharma beats Bright Minds Biosciences on 9 of the 13 factors compared between the two stocks.
Get Bright Minds Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for DRUG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DRUG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bright Minds Biosciences Competitors List
Related Companies and Tools
Free DRUG Stock Alerts